Immunomodulating effects of 3-thia fatty acids in activated peripheral blood mononuclear cells

European Journal of Clinical Investigation

Volumn 33, Issue 5, 2003, Pages 426-433

  Aukrust, P ^a,b   Wergedahl, H ^d   Muller F ^a,b   Ueland, T ^b,c   Dyroy E ^d   Damas J K ^b   Froland S S ^a,b   Berge, Rolf K ^d  

^a Sect Clin Immunol Infect Dis   (Norway)

^b Research Institute for Internal Medicine   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokines; Lymphocytes; Peroxisome proliferator activated receptor; Proliferation; Tetradecylthioacetic acid

Indexed keywords

FATTY ACID DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHYTOHEMAGGLUTININ; TETRADECYLTHIOACETIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; APOPTOSIS; CELL DIVISION; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038583636     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01140.x     Document Type: Article

References (38)

1. Berge RK, Hvattum E. Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharamacol Ther 1994;61:345-83.
2. Berge RK, Madsen L, Vaagenes H. Hypolipidemic 3-thia fatty acids. Fatty acid oxidation and ketogenesis in rat liver under proliferation of mitochondria and peroxisomes. Adv Exp Med Biol 1999;466:125-2.
3. Frøyland L, Madsen L, Vaagenes H, Totland GT, Auwerx J, Kryvi H et al. Mitochondrion is principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 1997;38:1851-8.
4. Raspe E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation. J Lipid Res 1999;40:2099-110.
5. Madsen L, Frøyland L, Grav H, Berge RK. Upregulated δ-9-desaturase gene expression by hypolipidemic peroxisome proliferating fatty acids resulted in increased oleic acid content in liver and VLDL. accumulation of a δ-9-desatureted metabolite of tetradecylthioacetic acid. J Lipid Res 1997;38:554-63.
6. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001;116:702-12.
7. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K et al. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 2001;22:1747-55.
8. Muna ZA, Doudin K, Songstad J, Ulvik RJ, Berge RK. Tetradecylthioacetic acid inhibits the oxidative modification of low density lipoprotein and 8-hydroxydeoxyguanosine formation in vitro. Arterioscler Thromb Vasc Biol 1997;17:3255-62.
9. Pettersen JT, Muna ZA, Kuiper KKJ, Svendsen E, Müller F, Aukrust P et al. Sustained retention of tetradecylthioacetate acid after local delivery reduces angioplasty-induced coronary stenosis in the minipig. Cardiovasc Res 2001;52:306-13.
10. Delerive P, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169:453-9.
11. Ross Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
12. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Solum NO et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina - possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-20.
13. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 2002;13:295-304.
14. Spydevold O, Bremer J. Induction of peroxisomal β-oxidation in 7800, C1 Morris hepatoma cells in steady state by fatty acids and fatty acid analogues. Biochim Biophys Acta 1989, 1003: 72-9.
15. Aukrust P, Müller F, Frøland SS. Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency. Clin Exp Immunol 1994;97:232-8.
16. Aukrust P, Aandahl EM, Skålhegg BS, Nordøy I, Hansson V, Taskén K et al. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol 1999;162:1178-85.
17. Stylianou E, Aukrust P, Bendtzen K, Müller F, Frøland SS. Interferons and interferon (IFN) inducible-protein 10 during highly active antiretroviral therapy (HAART) - possible immunosuppressive role of IFN-α in HIV infection. Cliskorve, Tronstad JK, N Exp Immunol 2000;117:479-85.
18. Yndestad A, Damås JK, Eiken HG, Holm T, Haug T, Simonsen S et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
19. Brekke OL, Espevik T, Bardal T, Bjerve KS. Effects of n-3 and n-6 fatty acids on tumor necrosis factor cytotoxicity in WEHI fibrosarcoma cells. Lipids 1992;27:161-8.
20. Toborek M, Blanc EM, Kaiser S, Mattson MP, Hennig B. Linoleic acid potentiates TNF-mediated oxidative stress, disruption of calcium homeostasis, and apoptosis of cultured vascular endothelial cells. J Lipid Res 1997;38:2155-67.
21. Mosmann TR. Properties and function of IL-10. Adv Immunol 1994;56:1-26.
22. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82.
23. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001;104:746-9.
24. Wæhre T, Halvorsen B, Damås JK, Brosstad F, Gullestad L, Kjekshus J et al. Inflammatory imbalance between IL-10 and TNFα in unstable angina - potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002;32:803-10.
25. Terkeltaub RA. IL-10: an 'immunologic scalpel' for atherosclerosis? Arterioscler Thromb Vasc Biol 1999;19:2823-5.
26. Katsikis PD, Chu C-Q, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
27. van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-9.
28. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H et al. IL-10 is a key cytokine in psoriasis. proof of principle by IL-10 therapy. J Clin Invest 1998;101:783-94.
29. Avula CP, Zaman AK, Lawrence R, Fernandes G. Induction of apoptosis and apoptotic mediators in Balb/C splenic lymphocytes by dietary n-3 and n-6 fatty acids. Lipids 1999;34:921-7.
30. Terano T, Tanaka T, Tamura Y, Kitagawa M, Higashi H, Saito Y et al. Eicosapentaenoic acid and docosahexaenoic acid inhibit vascular smooth muscle cell proliferation by inhibiting phosphorylation of Cdk2-cyclinE complex. Biochem Biophys Res Commun 1999;254:502-6.
31. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the antiinflammatory activity of peroxisome proliferator-activated receptorα activators. J Biol Chem 2000;275:36703-7.
32. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARγ dependent and independent effects of macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
33. Azuma Y, Shinohara M, Wang PL, Ohura K. 15-deoxy-delta(12,14)-prostaglandin J (2) inhibits IL-10 and IL-12 production by macrophages. Biochem Biophys Res Commun 2001;283: 344-6.
34. Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, Michel S. Differential expression of peroxisome proliferator-activator receptor subtypes during differentiation of human keratinocytes. J Invest Dermatol 1998;111:1116-21.
35. Shapiro AC, Wu D, Meydani SN. Eicosanoids derived from arachidonic and eicosapentaenoic acids inhibit T cell proliferative response. Prostaglandins 1993;45:229-40.
36. Sasaki T, Kanke Y, Kudoh K, Misawa Y, Shimizu J, Takita T. Effects of dietary docosahexaenoic acid on surface molecules involved in T cell proliferation. Biochem Biophys Acta 1999;1436:519-30.
37. Jolly CA, Jiang YH, Chapkin RS, McMurray DN. Dietary (n-3) polyunsaturated fatty acids suppress murine lymphoproliferafion, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. J Nutr 1997;127:37-43.
38. Costabile M, Hii CS, Robinson BS, Rathjen DA, Pitt M, Easton C et al. A novel long chain polyunsaturated fatty acid, beta-Oxa 21: 3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed-type hypersensitivity, and carrageenan-induced paw reaction and selectively targets intracellular signals. J Immunol 2001;167:3980-7.